Drug intelligence / Profile preview

GQ-401

Development stage: Preclinical
Lead developer: Pacira BioSciences
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies
Administration: Intradiscal

Overview

GQ-401 is a helper-dependent adenoviral gene therapy vector expressing an undisclosed therapeutic protein, under development for the treatment of intervertebral disc degeneration. The drug is being developed by GeneQuine Biotherapeutics GmbH (also referred to as GQ Bio Therapeutics GmbH). Its mechanism of action and specific target protein have not been publicly disclosed. As of the latest available information, GQ-401 remains in preclinical development for this indication[1][2][3].

Beyond the preview

Go deeper on GQ-401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GQ-401.

Explore the full profile